VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RDHL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RDHLRedHill Biopharma Ltd.
$0.86$4M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksRDHLBalance Sheet

RedHill Biopharma Ltd. (RDHL) Balance Sheet

14Y historyFree accessUpdated daily

Financial stability is severely compromised, with total assets contracting to $18.4 million and equity falling into a negative position of -$4.4 million as of 2025Q2.

RDHL Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Total Current Assets12.55M11.91M16.14M85.9M89.15M70.5M53.21M56.79M51.68M67.81M60.51M26.02M12.6M18.56M18.74M
Cash & Short-Term Investments2.87M4.62M6.36M19.98M38M29.79M47.87M53.19M46.2M66.15M58.14M22.95M12.11M18.36M18.65M
Cash Only2.87M4.62M5.57M19.97M29.47M29.3M29.02M29M16.45M53.79M21.52M5.89M11.85M16.81M14.07M
Short-Term Investments00790.04K15K8.53M498K18.85M24.18M29.75M12.37M36.62M17.05M262K1.55M4.58M
Accounts Receivable6.36M3.57M3.29M37.88M32.52M29.29M1.64M1.4M2.26M492K220K1.06M084K19K
Days Sales Outstanding170.22161.83183.62223.7138.43166.1194.8660.91206.051.78K26.77K55.37-1.92K301.52
Inventory3.17M3.65M4.39M11.01M14.81M6.53M1.88M769K653K1.11M-34.47M-15.04M-366K-951K-1.49M
Days Inventory Outstanding366.61417.49463.14120.54109.4164.57304.0998.94112.1113.31-----
Other Current Assets160K0797.04K16M00000000000
Total Non-Current Assets5.82M6.13M6.91M72.97M92.04M109.75M20.89M5.62M5.67M6.4M6.32M2.84M1.74M1.53M1.45M
Property, Plant & Equipment289K437K1.18M7.19M4.22M5.7M3.81M163K230K165K124K146K103K113K132K
Fixed Asset Turnover26.31x18.41x5.52x8.59x20.31x11.29x1.65x51.29x17.42x0.61x0.02x48.04x0.12x0.14x0.17x
Goodwill000000000000000
Intangible Assets5.53M5.55M5.58M65.63M71.64M87.88M16.93M5.32M5.29M6.09M6.06M2.62M1.55M1.34M1.25M
Long-Term Investments0148K147K150K16.17M0152K140K152K137K134K76K81K00
Other Non-Current Assets0041150K16.17M32.33M-20.73M-5.62M152K137K134K76K81K75K73K
Total Assets18.38M18.04M23.05M158.87M181.19M180.24M74.1M62.41M57.34M74.21M66.83M28.86M14.34M20.1M20.19M
Asset Turnover0.52x0.45x0.28x0.39x0.47x0.36x0.08x0.13x0.07x0.00x0.00x0.24x0.00x0.00x0.00x
Asset Growth %-76.56%-21.71%-85.49%-12.32%0.53%143.24%18.73%8.84%-22.73%11.05%131.59%101.23%-28.64%-0.45%-
Total Current Liabilities22.29M22.22M19.24M197.45M81.47M73.23M10.62M10.38M11.83M5.36M5.51M1.72M2.42M1.08M513K
Accounts Payable835K7.86M3.28M4.23M11.66M11.55M4.18M3.32M4.8M60K119K66K884K313K337K
Days Payables Outstanding287.57898.89345.946.3186.17114.3676.03427.66824.940.721.9722.94---
Short-Term Debt0353K718K115.22M1.62M1.71M000000000
Deferred Revenue (Current)000037.31M19.51M5.49M00000000
Other Current Liabilities10.55M10.96M10.76M49.65M12.03M-1.71M-2.89M1.46M1.06M393K325K320K1.33M615K124K
Current Ratio0.56x0.54x0.84x0.44x1.09x0.96x5.01x5.47x4.37x12.66x10.97x15.13x5.22x17.22x36.52x
Quick Ratio0.42x0.37x0.61x0.38x0.91x0.87x4.84x5.40x4.31x12.45x17.23x23.87x5.37x18.10x39.43x
Cash Conversion Cycle249.27-319.58300.85297.92161.67116.37-277.09-267.81-506.781.79K-----
Total Non-Current Liabilities500K503K1.74M9.82M90.84M93.14M3.48M844K448K6.16M1.24M2.13M00886K
Long-Term Debt000083.62M81.39M000000000
Capital Lease Obligations6K3K455K6.44M2.57M3.81M2.98M00000000
Deferred Tax Liabilities000000000000000
Other Non-Current Liabilities500K500K540K3.37M4.65M7.95M500K844K448K6.16M1.24M2.13M00886K
Total Liabilities22.79M22.73M20.98M207.27M172.31M166.38M14.1M11.22M12.28M11.51M6.75M3.85M2.42M1.08M1.4M
Total Debt214K356K1.17M122.69M87.81M86.9M3.81M00000000
Net Debt-2.65M-4.26M-4.4M102.72M58.34M57.61M-25.21M-29M-16.45M-53.79M-21.52M-5.89M-11.85M-16.81M-14.07M
Debt / Equity-0.05x-0.57x-9.89x6.27x0.06x--------
Debt / EBITDA-0.02x-0.08x------------
Net Debt / EBITDA0.26x--0.30x------------
Interest Coverage-7.99x-265.69x34.42x-1.04x-4.90x-5.12x-98.31x-235.51x-674.96x-4363.29x-1833.50x-483.95x-769.43x-6.10x-121.12x
Total Equity-4.41M-4.68M2.07M-48.4M8.88M13.86M60M51.19M45.06M62.7M60.08M25.01M11.93M19.02M18.79M
Equity Growth %-15318.26%-326.34%104.27%-645.35%-35.99%-76.89%17.22%13.58%-28.13%4.37%140.2%109.74%-37.3%1.23%-
Book Value per Share-2.45-1.903.99-390.7795.37190.301010.411106.961276.122434.052688.971433.79955.911807.971953.52
Total Shareholders' Equity-4.41M-4.68M2.07M-48.4M8.88M13.86M60M51.19M45.06M62.7M60.08M25.01M11.93M19.02M18.79M
Common Stock63.4M35.04M21.44M2.83M1.5M1.05M962K767K575K441K343K240K174K143K142K
Retained Earnings-418.12M-414.8M-407.74M-433.86M-367.87M-280.33M-208.36M-169.09M-132.94M-89.64M-61.94M-42.22M-33.26M-23.89M-15.21M
Treasury Stock000000000000000
Accumulated OCI0000000-341K-251K-170K-126K-90K-63K-39K-15K
Minority Interest000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency

Balance Sheet Erosion Accelerates Rapidly

According to recent financial statements, RedHill's total assets have plummeted from $58.8 million in 2023Q1 to just $18.4 million by 2025Q2, signaling a severe contraction in the company's resource base as it struggles to sustain operations amidst persistent, deep-seated operating losses.

The consistent decline in total assets suggests that the company is consuming its capital base to fund ongoing commercialization efforts rather than generating self-sustaining growth. This trajectory implies that the firm's ability to support its current infrastructure is rapidly diminishing, necessitating urgent strategic intervention.

Liquidity Buffer Nearing Critical Threshold

As reported in quarterly filings, the company's cash position has dwindled to $2.9 million as of 2025Q2, while the current ratio remains constrained at 0.56, indicating a significant inability to cover short-term obligations without immediate access to external financing or asset liquidation.

A current ratio consistently below 1.0 suggests that the company is operating in a state of chronic liquidity stress. Investors should monitor this closely, as the current cash runway appears insufficient to support the high fixed-cost structure required for its specialty GI product portfolio.

Equity Erosion Reflects Value Destruction

Based on the reported figures, RedHill's equity has shifted into negative territory at -$4.4 million as of 2025Q2, a stark reversal from the $3.5 million reported in 2023Q2, driven primarily by the accumulation of massive retained losses totaling over $418 million.

The transition to negative equity highlights the extent to which historical operating losses have eroded the company's book value. This trend suggests that shareholders are facing significant dilution risks, as the firm may be forced to issue equity to address its precarious solvency position.

Hidden Risks in Asset Valuation

Data from recent balance sheets reveals that goodwill remains stagnant at $5.5 million despite the company's deteriorating financial health, which may indicate an overvaluation of intangible assets that warrants further investigation for potential impairment risks in future reporting periods.

Maintaining high goodwill levels while the underlying business struggles to reach profitability suggests a potential disconnect between accounting valuations and market realities. If the company fails to achieve its commercial targets, these intangible assets could become a source of significant balance sheet volatility.

RDHL — Frequently Asked Questions

Quick answers to the most common questions about buying RDHL stock.

What are the total assets of RedHill Biopharma Ltd. (RDHL)?

As of 2024, RedHill Biopharma Ltd. (RDHL) had total assets of $18.0M including $11.9M in current assets.

How much debt does RedHill Biopharma Ltd. (RDHL) have?

RedHill Biopharma Ltd. (RDHL) carries total debt of $0.4M, offset by $4.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of RedHill Biopharma Ltd.?

RedHill Biopharma Ltd. (RDHL) has total shareholders' equity (book value) of $-4.7M ($-1.90 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is RedHill Biopharma Ltd.'s current ratio and liquidity?

RedHill Biopharma Ltd. (RDHL) reported a current ratio of 0.54x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.